Exchange: NASDAQ·Updated 04:26 PM EST

PBLS News

News
all
press releases
The mean of analysts' price targets for Parabilis Medicines (PBLS) points to a 44.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Parabilis Medicines, Inc. (NASDAQ:PBLS - Free Report) - Stock analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of Parabilis Medicines in a report issued on Friday, November 13th. HC Wainwright analyst R. Burns now forecasts that the company will post earni...
MarketBeat
Top Wall Street analysts changed outlook on top stocks. See full analyst rating changes & buy/sell recommendations for PBLS stock on Benzinga.read more...
Benzinga
Key PointsDirector Alan Sebulsky acquired 17,500 shares for $474,000, based on a weighted average purchase price of $27.06 per share...
Nasdaq News: Markets

Advertisement|Remove ads.